Increasing Daily Dose Of Ceftriaxone Does Not Increase Adverse Event Rates In Methicillin-Susceptible Staphylococcus Aureus, Study Finds

January 24, 2023

Infectious Disease Advisor (1/23, Nye) reports, “Increasing the daily dose of ceftriaxone for the treatment of methicillin-susceptible Staphylococcus aureus (MSSA) infection did not increase adverse event rates, according to” a “retrospective study” that...